IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors

被引：0
作者：
Aggen, David H.
McKean, Meredith
Hoffman-Censits, Jean H.
Lakhani, Nehal J.
Alhalabi, Omar
Guancial, Elizabeth A.
Bashir, Babar
Bowman, I. Alex
Tan, Alan
Lingaraj, Trupti
Kim, Katherine
Timothy, Marissa
Ortiz-Otero, Nerymar
Bartolini, Wilmin
Kacena, Katherine
Santillana, Sergio
Luke, Jason J.
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Johns Hopkins, Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Johns Hopkins, Johns Hopkins Greenberg Bladder Canc Inst, Sidney Kimmel Comprehens Canc Ctr, Dept Urol, Baltimore, MD USA
[6] START Midwest, Grand Rapids, MI USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[8] Florida Canc Specialists & Res Inst, Sarasota, FL USA
[9] Thomas Jefferson Univ, Sarah Cannon Res Inst, Philadelphia, PA 19107 USA
[10] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[11] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[12] Rush Univ, Med Ctr, Chicago, IL USA
[13] Ikena Oncol, Boston, MA USA
[14] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2599
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PD-1/L1 inhibitors can improve but not replace chemotherapy for advanced urothelial carcinoma: A systematic review and network meta-analysis
    Mao, Longkun
    Yang, Meihua
    Fan, Xinxiang
    Li, Wenjie
    Huang, Xiaodong
    He, Wang
    Lin, Tianxin
    Huang, Jian
    CANCER INNOVATION, 2023, 2 (03): : 191 - 202
  • [22] Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma
    Doshi, Gurjyot K.
    Li, Haojie
    Burcu, Mehmet
    Annavarapu, Srinivas
    Wells, Karen
    Imai, Kentaro
    Moreno, Blanca Homet
    Singhal, Puneet
    Mamtani, Ronac
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [23] Treatment patterns among patients with advanced urothelial carcinoma following discontinuation of PD1/L1 inhibitor therapy.
    Morgans, Alicia K.
    Grewal, Simrun Kaur
    Hepp, Zsolt
    Fuldeore, Rupali
    Odak, Shardul
    Macahilig, Cynthia
    Shillington, Alicia C.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [24] Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor
    Hwang, Inhwan
    Park, Inkeun
    Yoon, Shin-Kyo
    Lee, Jae Lyun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (04) : 371 - 377
  • [25] PD-L1, PD-1 expression associated with clinicopathologic characteristics of patients with upper tract urothelial carcinoma
    Li, Pengchao
    Lu, Qiang
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 : 44 - 44
  • [26] Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors
    Gao, Antian
    Pan, Xiao
    Yang, Xudong
    Lin, Zitong
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1132 - 1138
  • [27] Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors
    Antian Gao
    Xiao Pan
    Xudong Yang
    Zitong Lin
    Investigational New Drugs, 2021, 39 : 1132 - 1138
  • [28] A retrospective study of PD-1/PD-L1 combination therapy versus TKI monotherapy in elderly patients with uHCC
    Wang, Nanya
    Li, Yu
    Wang, Ying
    Liu, Bo
    Wang, Shibo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?
    Sonpavde, Guru
    Dranitsaris, George
    Necchi, Andrea
    EUROPEAN UROLOGY, 2018, 74 (01) : 63 - 65
  • [30] Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
    Zhong, Liting
    Peng, Weiwei
    Sun, Jingyuan
    Luo, Yongyi
    Sheng, Hailong
    Wu, Yi
    Zhou, Tonggang
    Zhou, Chaoming
    Cao, Chuanhui
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2025, 12 : 123 - 134
12345